Kevin A. Ingle

Kevin A. Ingle

Auto-generated profile, based on publicly available information

Kevin A. Ingle

Department of Cardiovascular Diseases, School of Medicine, The University of Alabama at Birmingham, Birmingham, AL 35294, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2018 in Science Signaling
Verified
Journal Article
Closed access
GHGanesh V Halade
Ganesh V Halade
PNPaul C. Norris
Paul C. Norris
VKVasundhara Kain
Vasundhara Kain
CSCharles Serhan
Charles Serhan
KIKevin A. Ingle
Kevin A. Ingle
Leukocytes may be the source of inflammation-resolving lipid mediators after myocardial infarction.

28 May 2022 in Molecules
Verified
Journal Article
Open access
PDF file
VKVeronika Kozlovskaya
Veronika Kozlovskaya
YYYiming Yang
Yiming Yang
FLFei Liu
Fei Liu
KIKevin Ingle
Kevin Ingle
AAAftab Ahmad
Aftab Ahmad
EKEugenia Kharlampieva
Eugenia Kharlampieva
Limited tissue selectivity and targeting of anticancer therapeutics in systemic administration can produce harmful side effects in the body. Various polymer nano-vehicles have been developed to encapsulate therapeutics and prevent premature drug release. Dually responsive polymeric vesicles (polymersomes) assembled from temperature-/pH-sensitive block copolymers are particularly interesting for the delivery of encapsulated therapeutics to targeted tumors and inflamed tissues. We have previously demonstrated that temperature-responsive poly(N-vinylcaprolactam) (PVCL)-b-poly(dimethylsiloxane) (PDMS)-b-PVCL polymersomes exhibit high loading efficiency of anticancer therapeutics in physiological conditions. However, the in-vivo toxicity of these polymersomes as biocompatible materials has not yet been explored. Nevertheless, developing an advanced therapeutic nanocarrier must provide the knowledge of possible risks from the material’s toxicity to support its future clinical research in humans. Herein, we studied pH-induced degradation of PVCL10-b-PDMS65-b-PVCL10 vesicles in-situ and their dually (pH- and temperature-) responsive release of the anticancer drug, doxorubicin, using NMR, DLS, TEM, and absorbance spectroscopy. The toxic potential of the polymersomes was evaluated in-vivo by intravenous injection (40 mg kg−1 single dose) of PVCL10-PDMS65-PVCL10 vesicles to mice. The sub-acute toxicity study (14 days) included gravimetric, histological, and hematological analyses and provided evidence for good biocompatibility and non-toxicity of the biomaterial. These results show the potential of these vesicles to be used in clinical research.